Open an account

Immuneering

IMRX · NASDAQ

$3.73+$0.07 (+1.91%)TodayMarket closed ·
Prev close $3.66

About IMRX

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Employees
55
Headquarters
Cambridge, Massachusetts
Listed
Jul 30, 2021
Sector
Health Care
Industry
Biotechnology
Website
immuneering.com

IMRX key statistics

Market cap
241.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
701.07K
Volume
926.90K
Open price
$3.69
High today
$3.84
Low today
$3.67
52 Week high
$8.48
52 Week low
$3.38

Immuneering (IMRX) at a glance

As of Oct 20, 2026, Immuneering (IMRX) shares are priced at $3.73, giving the company a market cap of 241.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.67 and $3.84. The current price is 1.6% above the day's low and 2.9% below its high.

Volume so far is 926.90K shares, above the average of 701.07K shares a day.

Over the past year Immuneering has ranged from $3.38 to $8.48, and now sits 7% of the way up that range.

Immuneering met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.2734.

The average analyst price target is $17.51, 369.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $17.51
Low
$12.12
Now
$3.73
High
$31.50

IMRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 15.5% on average.

  1. Q3 FY24: reported -$0.49 per share against an estimate of -$0.5625
  2. Q4 FY24: reported -$0.58 per share against an estimate of -$0.4723
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.5372
  4. Q2 FY25: reported -$0.40 per share against an estimate of -$0.4233
  5. Q3 FY25: reported -$0.38 per share against an estimate of -$0.3998
  6. Q4 FY25: reported -$0.18 per share against an estimate of -$0.3196
  7. Q1 FY26: reported -$0.21 per share against an estimate of -$0.257
  8. Q2 FY26: reported -$0.27 per share against an estimate of -$0.2734

IMRX news

  • Press releaseGlobe Newswire

    Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

  • Avi Kapoor

    Crude Oil Edges Higher; US Consumer Sentiment Falls In May

  • Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet

  • Avi Kapoor

    Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

  • Avi Kapoor

    Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

  • Press releasePRNewswire

    Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

  • Press releaseGlobe Newswire

    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

Similar companies

Companies in the same industry as Immuneering

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.